These findings further support the hypothesis of bi-directional crosstalk between the ER and HER2 pathways in breast cancer, which can lead to the activation of an alternative “escape” survival pathway (e.g., ER signaling) that gives rise to the development of acquired treatment resistance. Here, ESR1 is linked to breast cancer.